Table 1.
Age at time of treatment (years) | |
Median | 56 |
Range | 12–85 |
Patients (n = 16) | |
Male | 7 (44%) |
Female | 9 (56%) |
Lesions (n = 25) | |
Peripheral | 19 (76%) |
Central | 6 (24%) |
Histology | |
Leiomyosarcoma | 7 |
Synovial cell | 5 |
Osteosarcoma | 4 |
Liposarcoma | 2 |
NOS | 2 |
Spindle cell | 1 |
Chondrosarcoma | 1 |
Liposarcoma | 1 |
Hemangiopericytoma | 1 |
Embryonal | 1 |
Dose fractionation and BED* | |
54 Gy, 3 fractions (BED = 151.2 Gy) | 13 (52%) |
50 Gy, 4 fractions (BED = 112.5 Gy) | 9 (36%) |
36 Gy, 3 fractions (BED = 79.2 Gy) | 2 (8%) |
42 Gy, 3 fractions (BED = 100.8 Gy) | 1 (4%) |
*Biological equivalent dose is calculated per (1), assuming α/β ratio of 10 for tumor (n = number of fractions, d = total dose).